2558 related articles for article (PubMed ID: 27127018)
21. The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer.
Jensen MB; Lænkholm AV; Nielsen TO; Eriksen JO; Wehn P; Hood T; Ram N; Buckingham W; Ferree S; Ejlertsen B
Breast Cancer Res; 2018 Jul; 20(1):79. PubMed ID: 30053900
[TBL] [Abstract][Full Text] [Related]
22. Adjuvant systemic therapy for women with node-positive breast cancer. The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.
CMAJ; 1998 Feb; 158 Suppl 3():S52-64. PubMed ID: 9484279
[TBL] [Abstract][Full Text] [Related]
23. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
Sharma R; Hamilton A; Beith J
Cochrane Database Syst Rev; 2008 Oct; (4):CD004562. PubMed ID: 18843661
[TBL] [Abstract][Full Text] [Related]
24. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial.
Overgaard M; Hansen PS; Overgaard J; Rose C; Andersson M; Bach F; Kjaer M; Gadeberg CC; Mouridsen HT; Jensen MB; Zedeler K
N Engl J Med; 1997 Oct; 337(14):949-55. PubMed ID: 9395428
[TBL] [Abstract][Full Text] [Related]
25. Lack of TIMP-1 tumour cell immunoreactivity predicts effect of adjuvant anthracycline-based chemotherapy in patients (n=647) with primary breast cancer. A Danish Breast Cancer Cooperative Group Study.
Willemoe GL; Hertel PB; Bartels A; Jensen MB; Balslev E; Rasmussen BB; Mouridsen H; Ejlertsen B; Brünner N
Eur J Cancer; 2009 Sep; 45(14):2528-36. PubMed ID: 19535243
[TBL] [Abstract][Full Text] [Related]
26. WITHDRAWN: Multi-agent chemotherapy for early breast cancer.
Clarke MJ
Cochrane Database Syst Rev; 2008 Oct; 2008(4):CD000487. PubMed ID: 18843612
[TBL] [Abstract][Full Text] [Related]
27. retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group.
Knoop AS; Knudsen H; Balslev E; Rasmussen BB; Overgaard J; Nielsen KV; Schonau A; Gunnarsdóttir K; Olsen KE; Mouridsen H; Ejlertsen B;
J Clin Oncol; 2005 Oct; 23(30):7483-90. PubMed ID: 16234514
[TBL] [Abstract][Full Text] [Related]
28. CEF is superior to CMF for tumours with TOP2A aberrations: a Subpopulation Treatment Effect Pattern Plot (STEPP) analysis on Danish Breast Cancer Cooperative Group Study 89D.
Gunnarsdóttir KA; Jensen MB; Zahrieh D; Gelber RD; Knoop A; Bonetti M; Mouridsen H; Ejlertsen B
Breast Cancer Res Treat; 2010 Aug; 123(1):163-9. PubMed ID: 20464479
[TBL] [Abstract][Full Text] [Related]
29. Tamoxifen in high-risk premenopausal women with primary breast cancer receiving adjuvant chemotherapy. Report from the Danish Breast Cancer co-operative Group DBCG 82B Trial.
Andersson M; Kamby C; Jensen MB; Mouridsen H; Ejlertsen B; Dombernowsky P; Rose C; Cold S; Overgaard M; Andersen J; Kjaer M
Eur J Cancer; 1999 Nov; 35(12):1659-66. PubMed ID: 10674010
[TBL] [Abstract][Full Text] [Related]
30. The curability of breast cancer and the treatment of advanced disease.
Guarneri V; Conte PF
Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S149-61. PubMed ID: 15107948
[TBL] [Abstract][Full Text] [Related]
31. Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial.
International Breast Cancer Study Group (IBCSG)
J Natl Cancer Inst; 2002 Jul; 94(14):1054-65. PubMed ID: 12122096
[TBL] [Abstract][Full Text] [Related]
32. Randomised trial: One cycle of anthracycline-containing adjuvant chemotherapy compared with six cycles of CMF treatment in node-positive, hormone receptor-negative breast cancer patients.
Ploner F; Jakesz R; Hausmaninger H; Kolb R; Stierer M; Fridrik M; Steindorfer P; Gnant M; Haider K; Mlineritsch B; Tschurtschenthaler G; Steger G; Seifert M; Kubista E; Samonigg H;
Onkologie; 2003 Apr; 26(2):115-9. PubMed ID: 12771518
[TBL] [Abstract][Full Text] [Related]
33. Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy.
Lin YC; Chen SC; Chang HK; Hsueh S; Tsai CS; Lo YF; Hwang TL; Chen MF
Jpn J Clin Oncol; 2005 Sep; 35(9):514-9. PubMed ID: 16199422
[TBL] [Abstract][Full Text] [Related]
34. Adjuvant randomized trials of doxorubicin/cyclophosphamide versus doxorubicin/cyclophosphamide/tamoxifen and CMF chemotherapy versus tamoxifen in women with node-positive breast cancer.
Kaufmann M; Jonat W; Abel U; Hilfrich J; Caffier H; Kreienberg R; Trams G; Brunnert K; Schermann J; Kleine W
J Clin Oncol; 1993 Mar; 11(3):454-60. PubMed ID: 8445420
[TBL] [Abstract][Full Text] [Related]
35. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.
Francis P; Crown J; Di Leo A; Buyse M; Balil A; Andersson M; Nordenskjöld B; Lang I; Jakesz R; Vorobiof D; Gutiérrez J; van Hazel G; Dolci S; Jamin S; Bendahmane B; Gelber RD; Goldhirsch A; Castiglione-Gertsch M; Piccart-Gebhart M;
J Natl Cancer Inst; 2008 Jan; 100(2):121-33. PubMed ID: 18182617
[TBL] [Abstract][Full Text] [Related]
36. Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration.
Misset JL; di Palma M; Delgado M; Plagne R; Chollet P; Fumoleau P; Le Mevel B; Belpomme D; Guerrin J; Fargeot P; Metz R; Ithzaki M; Hill C; Mathé G
J Clin Oncol; 1996 Apr; 14(4):1136-45. PubMed ID: 8648368
[TBL] [Abstract][Full Text] [Related]
37. Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer.
Poole CJ; Earl HM; Hiller L; Dunn JA; Bathers S; Grieve RJ; Spooner DA; Agrawal RK; Fernando IN; Brunt AM; O'Reilly SM; Crawford SM; Rea DW; Simmonds P; Mansi JL; Stanley A; Harvey P; McAdam K; Foster L; Leonard RC; Twelves CJ;
N Engl J Med; 2006 Nov; 355(18):1851-62. PubMed ID: 17079759
[TBL] [Abstract][Full Text] [Related]
38. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII.
Crivellari D; Bonetti M; Castiglione-Gertsch M; Gelber RD; Rudenstam CM; Thürlimann B; Price KN; Coates AS; Hürny C; Bernhard J; Lindtner J; Collins J; Senn HJ; Cavalli F; Forbes J; Gudgeon A; Simoncini E; Cortes-Funes H; Veronesi A; Fey M; Goldhirsch A
J Clin Oncol; 2000 Apr; 18(7):1412-22. PubMed ID: 10735888
[TBL] [Abstract][Full Text] [Related]
39. Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer.
Bui KT; Willson ML; Goel S; Beith J; Goodwin A
Cochrane Database Syst Rev; 2020 Mar; 3(3):CD013538. PubMed ID: 32141074
[TBL] [Abstract][Full Text] [Related]
40. Taxanes for adjuvant treatment of early breast cancer.
Willson ML; Burke L; Ferguson T; Ghersi D; Nowak AK; Wilcken N
Cochrane Database Syst Rev; 2019 Sep; 9(9):CD004421. PubMed ID: 31476253
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]